Editorial

Pareto's Law and Sulfonylureas

Authors: Alan N. Peiris, MD, PhD, MRCP(UK), Melinda Micklewright, BSPharm, BCPS, Venkataramanan Gangadharan, MD

Abstract

Italian economist Vilfredo Pareto observed that 80% of income in Italy went to only 20% of the population. Since then, the universality of this 80–20 rule has been widely recognized. One such application is sulfonylurea dose responses in the treatment of diabetes, with the majority of benefit coming from small introductory doses as elegantly shown by Rambiritch et al.1 Clinical practitioners using sulfonylureas have seen both sides of the dosage spectrum. Peters2 reported benefit from using maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes, while Stenman3 reported that minimal doses of glipizide were effective and larger doses may actually induce deterioration in beta cell response.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Rambiritch V, Naidoo P, Butkow N. Dose-response relationships of Sulphonylureas: will doubling the dose double the response? South Med J 2007;100:1132–1136.
 
2. Peters AL, Davidson MB. Maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes: a new use for an old friend. J Clin Endocrinol Metab 1996;81:2423–2427.
 
3. Stenman S, Melander A, Groop PH, et al. What is the benefit of increasing the sulfonylurea dose?Ann Intern Med 1993;118:169–172.
 
4. Grunberger G. Maintenance of sulfonylurea responsiveness in NIDDM. Randomized double-blind study of intermittent glyburide therapy. Diabetes Care 1992;15:696–699.
 
5. Simpson SH, Majumdar SR, Tsuyuki RT. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006;174:169–174.
 
6. Monami M, Luzzi C, Lamanna C, et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006;22:477–482.
 
7. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003;88:531–537.
 
8. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254–258.